real-time news and commentary for investors
Tuesday, Mar 19
Sarepta Therapeutics (SRPT +1.8%) gains this morning after Deutsche Bank SRPT) with a Buy rating...
Sarepta Therapeutics (SRPT +1.8%) gains this morning after Deutsche Bank starts coverage with a Buy. Deutsche says SRPT's Eteplirsen, a treatment for Duchenne Muscular Dystrophy, is likely will be given the green light by mid-2015. The drug has a better safety profile versus its competitor Drisapersen, which will allow it to take a majority share. Fair-value of Eteplirsen in the U.S. alone is around $45 per share, and has tremendous upside potential if the street assigns value to European markets.